Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE AND ELRANATAMAB IN COMBINATION WITH PF-07901801 IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA

NCT05675449 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05675449
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05675449 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE AND ELRANATAMAB IN COMBINATION WITH PF-07901801 IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Active, not recruiting
Start date
December 14, 2022
Completion date
February 29, 2028
Enrollment
59 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma